Sinopharm Group Co. Ltd (X2S) — Cash Flow-to-Debt Ratio
Sinopharm Group Co. Ltd (X2S) has a Cash Flow-to-Debt Ratio of -0.01x as of June 2023, meaning its operating cash flow of €-2.63 Billion could theoretically repay 0% of its total liabilities (€304.58 Billion) in one year. Explore long-term investment intensity of Sinopharm Group Co. Ltd to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sinopharm Group Co. Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Sinopharm Group Co. Ltd across 13 annual periods. Also explore X2S total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Sinopharm Group Co. Ltd (2013–2025)
Year-by-year debt coverage analysis for Sinopharm Group Co. Ltd. For market capitalisation and broader financial context, see Sinopharm Group Co. Ltd market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | €14.14 Billion | €256.20 Billion | ▲ +27.2% |
| 2024 | 0.04x | €11.55 Billion | €266.14 Billion | ▼ -33.5% |
| 2023 | 0.07x | €17.17 Billion | €263.08 Billion | ▼ -20.7% |
| 2022 | 0.08x | €20.96 Billion | €254.71 Billion | ▲ +108.5% |
| 2021 | 0.04x | €9.31 Billion | €235.76 Billion | ▼ -21.7% |
| 2020 | 0.05x | €11.15 Billion | €221.29 Billion | ▼ -48.2% |
| 2019 | 0.10x | €18.78 Billion | €192.95 Billion | ▲ +346.1% |
| 2018 | 0.02x | €3.65 Billion | €167.50 Billion | ▼ -19.6% |
| 2017 | 0.03x | €3.21 Billion | €118.27 Billion | ▼ -66.8% |
| 2016 | 0.08x | €9.26 Billion | €113.18 Billion | ▼ -39.9% |
| 2015 | 0.14x | €13.41 Billion | €98.55 Billion | ▲ +126.1% |
| 2014 | 0.06x | €5.56 Billion | €92.37 Billion | ▼ -6.4% |
| 2013 | 0.06x | €4.94 Billion | €76.84 Billion | — |